Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
PT Jayamas Medica Industri Tbk's revenue for the
three
months ended in Jun. 2026 was Rp594,545 Mil.
Its revenue for the trailing twelve months (TTM) ended in Jun. 2026 was Rp2,304,764 Mil.
PT Jayamas Medica Industri Tbk's Revenue per Share for the
three
months ended in Jun. 2026 was Rp21.96.
Its Revenue per Share for the trailing twelve months (TTM) ended in Jun. 2026 was Rp85.26.
During the past 7 years, PT Jayamas Medica Industri Tbk's highest 3-Year average Revenue per Share Growth Rate was 12.30% per year. The lowest was -5.40% per year. And the median was 0.70% per year.
His favorite companies are stalwart, those growing between 10-20% a year.
Companies in cyclical industries may see their revenue fluctuate wildly in good years and bad years.
Be Aware
Revenue can be manipulated by changing the way how revenue is booked. Companies may book sales before the payment is received, or before the revenue is fully earned. These will be added to balance sheet items such as account payable or account receivables.
PT Jayamas Medica Industri Tbk Revenue Related Terms
PT Jayamas Medica Industri Tbk Revenue Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Medical Instruments & Supplies subindustry, PT Jayamas Medica Industri Tbk's Revenue, along with its competitors' market caps and Revenue data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
PT Jayamas Medica Industri Tbk Revenue vs Medical Devices & Instruments Industry
For the Medical Devices & Instruments industry and Healthcare sector, PT Jayamas Medica Industri Tbk's Revenue distribution charts can be found below:
* The bar in red indicates where PT Jayamas Medica Industri Tbk's Revenue falls into.
PT Jayamas Medica Industri Tbk Revenue Calculation
Also referred as sales, revenue is income that a company receives from its normal business activities, usually from the sale of goods and services to customers. Revenue is often referred to as the "top line" due to its position on the income statement at the very top.
Revenue for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was Rp2,304,764 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
PT Jayamas Medica Industri Tbk (ISX:OMED) has a Revenue of Rp2,304,764 Mil as of Jun. 2026. Revenue is the total amount a company generates as sales through its operations. View historical data on PT Jayamas Medica Industri Tbk and its competitors.
Is PT Jayamas Medica Industri Tbk's Revenue too high?
PT Jayamas Medica Industri Tbk's current Revenue is Rp2,304,764 Mil. Overall, PT Jayamas Medica Industri Tbk has a GF Score™ of 90/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does PT Jayamas Medica Industri Tbk's Revenue compare to ISRG and BDX?
PT Jayamas Medica Industri Tbk's Revenue of Rp2,304,764 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Revenue for a Medical Devices & Instruments company?
A good Revenue depends on the Medical Devices & Instruments industry context. However, Revenue should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Revenue mean?
A high Revenue can signal that a stock is expensive relative to its fundamentals. Revenue is the total amount a company generates as sales through its operations. View historical data on PT Jayamas Medica Industri Tbk and its competitors. PT Jayamas Medica Industri Tbk's current Revenue is Rp2,304,764 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is PT Jayamas Medica Industri Tbk stock overvalued right now?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk (ISX:OMED) is currently considered Fairly Valued. The stock's GF Value™ is Rp239.50, compared to a current price of Rp234.00 — trading 2.3% below its estimated fair value. The current Revenue is Rp2,304,764 Mil. PT Jayamas Medica Industri Tbk's overall GF Score™ is 90/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Revenue calculated?
Revenue is calculated from a company's financial statements. For PT Jayamas Medica Industri Tbk (ISX:OMED), the current Revenue is Rp2,304,764 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is PT Jayamas Medica Industri Tbk (ISX:OMED) Overvalued in 2026?
Based on GuruFocus' analysis, PT Jayamas Medica Industri Tbk stock appears to be undervalued.
The current stock price of Rp234.00 is trading 2.3% below its estimated GF Value™ of Rp239.50.
GuruFocus considers PT Jayamas Medica Industri Tbk to be Fairly Valued.
Key valuation signals for ISX:OMED:
Revenue: Rp2,304,764 Mil
GF Value™: Rp239.50 vs. price of Rp234.00 (2.3% below fair value)
No single metric tells the full story. See the ISX:OMED stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
PT Jayamas Medica Industri Tbk is engaged in the business of manufacturing, wholesale and retail trade of medical devices. Its offerings include Disposable and Expendable Medical Supplies, Wound Care, Diagnostics and Equipment, Antiseptics and Dialysis, Biotechnology and Laboratory, Ambulatory and Rehabilitation Care The company has three segments: i) Manufacturing: This division is involved in the manufacturing of medical supplies and equipment, ii) Distribution: This division is involved with the large scale distribution of medical supplies and equipment at strategic locations, iii) Retail: This division is involved with the retail of medical supplies and equipment through Medicom stores and online platforms. The majority of the company's revenue is derived from the Distribution segment.
90GF Score
Get the complete analysis for ISX:OMED
Revenue is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ISX:OMED has been successfully added to your 
